Thyrotropin Receptor Antibodies-An Overview

Area of Science:

• Endocrinology
• Immunology
• Clinical Diagnostics

Background:

• Thyroid autoimmunity impacts ~5% of the population, necessitating reliable autoantibody testing.
• Thyroid stimulating hormone receptor autoantibodies (TRAb) are key biomarkers for Graves disease (GD), Graves ophthalmopathy (GO), and pretibial myxedema (PTM).

Purpose of the Study:

• To review and analyze the diagnostic accuracy and prognostic utility of TRAb assays.
• To explore the clinical relevance of TRAb in various thyroid-related conditions.

Main Methods:

• Literature review and analysis of studies reporting on TRAb assays.
• Examination of different TRAb assay methodologies, including TSH binding inhibiting immunoglobulin and thyroid stimulating immunoglobulin assays.

Main Results:

• Current TRAb assays, while improved in sensitivity and specificity, measure overall titer or biologic activity.
• TRAb testing is vital in specific hyperthyroidism cases (e.g., pregnancy) and for diagnosing euthyroid eye disease suspicious for GO.
• Third-generation TRAb assays offer value in therapy selection for GD, prognostic predictions for GO, and risk assessment for fetal/neonatal thyrotoxicosis.

Conclusions:

• TRAb assays are essential for evaluating and managing thyroid autoimmune diseases.
• Future research on TRAb is expected to refine predictive roles for therapeutic efficacy in GO and PTM, and explore novel applications in thyroid cancer therapy.